Tenofovir Alafenamide
| Evidence Level: L5 | Predicted Indications: 10 |
Table of Contents
- Tenofovir Alafenamide
- Tenofovir Alafenamide: From HIV-1 Infection to Feline Acquired Immunodeficiency Syndrome
Tenofovir Alafenamide: From HIV-1 Infection to Feline Acquired Immunodeficiency Syndrome
One-Sentence Summary
Tenofovir alafenamide (TAF) is a nucleotide reverse transcriptase inhibitor prodrug, originally developed for HIV-1 infection and later extended to chronic hepatitis B. The TxGNN model’s top-ranked prediction points to Feline Acquired Immunodeficiency Syndrome (FIV) — a veterinary lentivirus disease — with a prediction score of 99.89%, but this candidate is currently supported by 0 clinical trials and 0 publications, making it a pure AI-generated hypothesis with no direct evidence and no human clinical relevance.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Not captured in the EU authorization records provided (0 licenses on file); based on contextual information in this evidence pack, TAF is originally indicated for HIV-1 infection and chronic hepatitis B |
| Predicted New Indication | Feline Acquired Immunodeficiency Syndrome (FIV) — a veterinary indication, not a human disease |
| TxGNN Prediction Score | 99.89% |
| Evidence Level | L5 |
| EU Market Status | ✗ Not marketed |
| Number of Authorizations | 0 |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
Currently, detailed mechanism of action data is not available (flagged as a High-severity data gap in this evidence pack). Based on known information, tenofovir alafenamide is a prodrug of tenofovir that inhibits viral reverse transcriptase; it is used as part of antiretroviral combination regimens, and its efficacy in HIV-1 infection is well established.
The mechanistic link proposed by TxGNN is that Feline Immunodeficiency Virus (FIV) and HIV are both lentiviruses that depend on reverse transcriptase for replication, so a reverse-transcriptase inhibitor like TAF is theoretically plausible against FIV. However, this rationale — as noted directly in the underlying repurposing rationale for this candidate — describes a veterinary indication, not a human clinical development target. There is no supporting clinical trial, no publication, and no regulatory pathway relevant to human drug repurposing for this pairing.
In short, the mechanistic plausibility is real at the level of viral biology, but the target disease itself falls entirely outside the scope of human pharmaceutical repurposing, which is why the evidence level remains at the lowest tier (L5 — model prediction only, no actual studies).
Clinical Trial Evidence
Currently no related clinical trials registered
Literature Evidence
Currently no related literature available
EU Market Information
No EU marketing authorization is currently on file for tenofovir alafenamide in this evidence pack (EU market status: Not marketed; 0 authorizations recorded).
Safety Considerations
Please refer to the SmPC for safety information.
Conclusion and Next Steps
Decision: Hold
Rationale: The top-ranked TxGNN candidate (Feline Acquired Immunodeficiency Syndrome) has a high similarity score but zero clinical trial or literature support, and it describes a veterinary rather than human disease — it is not a viable human drug repurposing target as currently framed.
To proceed, the following is needed:
- Mechanism of action (MOA) data from DrugBank to properly evaluate mechanistic relevance across candidates
- TFDA/EMA-equivalent SmPC warnings and contraindications, which are currently a blocking data gap for any S1 safety evaluation
- Re-triage of the full predicted-indication list to separate genuine repurposing candidates from noise (veterinary indications, animal-model surrogates such as SIV/SHIV, obsolete disease terms, and pairings that actually represent TAF’s existing approved indications — e.g., hepatitis B virus infection and congenital/perinatal HIV — rather than novel repurposing opportunities)
- Confirmation of EU marketing authorization status, since 0 licenses are currently on record for this product
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.